MENU

Pro Medicus Limited (ASX:PME) shares storm to an all-time high on bumper profit growth

In early trade the Pro Medicus Limited (ASX: PME) share price pushed 4.5% higher to an all-time high of $9.09 following the release of the imaging IT provider’s full year results.

For the 12 months ended June 30 2018, Pro Medicus posted a 13.9% increase in revenue to $36 million and a 36.7% jump in profit after tax to $12.7 million. Underlying profit, excluding currency movements, was up 27.4% to $12.6 million.

As shown below, the main driver of this growth was the positive performance of its North American and European operations. Revenue in these segments increased 18.4% and 33.2%, respectively, in FY 2018. This made up for a soft performance from its Australian operation.

Source: Company presentation

The North American segment was given a boost from the signing of three key contracts. This included an A$18 million, seven-year contract with Yale New Haven Health, one of the leading academic institutions and a A$15 million, seven-year contract with Mercy Health for Visage Open Archive.

Pro Medicus’ strong bottom line growth was largely down to its North American business. CEO Sam Hupert stated that: “The key driver for margin and revenue growth was our North American business. We brought more sites online so had a good year in terms of professional services, which includes implementation and training. Those sites that were online continued to build their transaction volumes which is pretty much what we expected, so we’re very pleased with that.”

Before adding that: “Looking at margins, we’ve always said that the US is a higher margin business and therefore the greater the contribution from the US the higher the margins in total. As we grow this business and build our base of recurring transaction revenues in that market we should see further margin expansion.”

This ultimately led to earnings per share of 12.2 cents, up from 9 cents per share in FY 2017. And with the company remaining debt-free and seeing its cash reserves rise 10.8% to $25.2 million, the board was able to increase its full-year dividend by 50% to a fully franked 6 cents per share.

Should you invest?

As I mentioned yesterday, I think Pro Medicus is up there with Nanosonics Ltd (ASX: NAN) and Volpara Health Technologies Ltd (ASX: VHT) as one of the best medical technology shares on the Australian share market.

There’s no denying that its shares are expensive at 75x earnings and carry a lot of risk, but I remain confident that it can grow at a level that justifies this premium over the long-term.

As well as Pro Medicus, here are three other top mid cap shares to back in FY 2019.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Atlassian.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited, PRO Medicus Ltd., and VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.